Search PubMed⌕ Search

Biomedical subjects

S Oparil

Publications and source records attributed to S Oparil.

At least 307 records · Page 17Linked to original sources
PubMed1978

Effects of constituent amino acids on tubular handling of microinfused angiotensin II.

[14C]angiotensin II ([14C]AII) was microinjected alone or with excess L-isoleucine (IIe) or L-aspartic acid (Asp) into renal tubules of anesthetized rats. Urinary excretion of 14C-labeled material was measured, and the intact peptide and its metabolites were identified and quantified. When isoleucine was administered with [14C]AII, urinary recovery of the 14C-labeled material increased directly with distance of infusion site from glomerulus, and most of the radioactivity in urine was [14C]Ile. The data suggest that isoleucine interfered with reabsorption of [14C]Ile derived from hydrolysis of [14C]AII and less so with the hydrolysis itself. When aspartic acid was administered with [14C]AII into the proximal 5/6 of the proximal convolution, total urinary recovery of the 14C-labeled material was unchanged, but percentage of recovery as [14C]AII increased; with infusion into the distal 1/6 of the proximal convolution, total urinary recovery of the 14C labele increased. The data suggest that aspartic acid interfered with the enzymatic hydrolysis of [14C]AII and reabsorption of isoleucine. In distal tubules the 14C label was almost completely recovered as intact [14C]AII in all protocols. The results show that free amino acids influence proximal tubular handling of small linear peptides in rats.

Angiotensin II↗
PubMed1978

Inhibition of renin release from rat kidney slices by the angiotensins.

The mechanism and structural basis of the inhibition of renin release by angiotensin II (AII) were studied in rat kidney slices. Renin release was inhibited by AII and the (2-8), (3-8), (4-8), and (5-8) peptides of AII (5 X 10(-5) M). These constituent peptides of AII which share a common carboxyl terminus inhibited renin release with a sharp decrease in potency when the amino-terminal amino acid was removed. Saralasin attenuated the inhibition of renin release induced by equimolar concentrations of AII. Dose-response curves for AII and the (2-8) peptide [angiotensin III (AIII)] indicate that AII is a more potent inhibitor of renin release than is AIII. Depletion of renal norepinephrine by reserpine (10 mg/kg, i.p.) or pretreatment of slices with papaverine (1 X 10(-4) M) did not block the action of AII. The data give evidence for a direct action of AII on the juxtaglomerular cells independent of an interaction with either the sympathetic nervous system or the arteriolar baroreceptor and suggest that the intrarenal receptors that mediate AII-induced inhibition of renin release differ from AII receptors in the adrenal cortex.

Angiotensin II↗
PubMed1977

Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro.

In order to study renal tubular handling of two small peptide hormones, [14c]angiotensin II ([14C]AII) and [3H]oxytocin ([3H]OT) were microperfused through rabbit kidney tubule segments in vitro. The reabsorption and tubular sequestration of radioactive label were determined, and the collection fluid was electrophoretically analyzed. The data suggest that [14C]AII is extensively hydrolyzed in the pars recta of the nephron and is rapidly reabsorbed across the tubular epithelium. Under similar experimental conditions, hydrolysis of [3H]OT was not observed in either the proximal straight or cortical collecting tubule segment, and the rate of reabsorption was low. Thus, tubular handling of OT appears to differ from that of AII, probably because of differences in molecular structure.

Angiotensin II↗
PubMed1977

Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy.

The effects of peripheral sympathectomy with nerve growth factor antiserum (NGFAS) on blood pressure, systemic hemodynamics, myocardial function, myocardial hypertrophy, and renin were studied in male spontaneously hypertensive (SH) rats of the Okamoto strain and normotensive control Kyoto-Wistar (WKY) rats. NGFAS prevented the developing of hypertension in the SH rats but did not alter blood pressure in the WKY rats. The NGFAS-treated SH rats developed the same hemodynamic abnormalities as the sham-treated rats, including increased peripheral vascular resistance and depressed cardiac output; Indices of left ventricular performance, including peak flow velocity, stroke power, stroke work, dP/dtmax, and flow acceleration (dF/dt), were diminished in the SH rats compared to the WKY rats. NGFAS treatment further depressed ventricular function in the SH rats, but had little effect on the WKY rats; Plasma renin activity in both the SH and WKY rats was unaffected by NGFAS treatment. Although NGFAS treatment effectively prevented the development of hypertension in the SH rats, it did not influence the development of left ventricular hypertrophy as reflected by increases in left ventricular mass, RNA, DNA, and hydroxyproline content. The data suggest that the development of myocardial hypertrophy and myocardial dysfunction in the SH rat is in part independent of hypertension and plasma renin activity.

Animals↗
PubMed1976

Altered angiotensin I conversion in pulmonary disease.

1. A specific method is described for the measurement of angiotensin I converting enzyme activity in plasma with 125 I-labelled angiotensin I used as substrate. 2. Converting enzyme activity in plasma from fifteen normal subjects, eleven patients with sarcoidosis, twelve patients with chronic obstructive pulmonary disease and three patients with shock lung was assayed by this technique. 3. Patients with sarcoidosis had increased plasma converting enzyme activity whether or not they were receiving steroid therapy. 4. Patients with chronic obstructive pulmonary disease and shock lung had decreased plasma converting enzyme activity, but extent of conversion did not correlate with the severity of the lung disease. 5. Converting enzyme activity in normal plasma could be completely inhibited by addition of exogenous angiotensin I in 0.5-2.5x107 times physiological concentration. Twice as much exogenous angiotensin I was needed to inhibit conversion completely in plasma from patients with sarcoidosis; one tenth as much in chronic obstructive pulmonary disease. These results indicate that plasma has a high capacity for angiotensin I conversion even in patients with pulmonary parenchymal disease. 6. Results suggest that plasma converting enzyme activity may be a reflection of pulmonary conversion and can be altered by pulmonary disease. 7. Measurement of plasma converting enzyme activity may be useful in studies designed to characterize the regulatory role of converting enzyme in the renin-angiotensin system and in cardiovascular homeostasis.

Angiotensin II↗
PubMed1976

Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule.

3H-labeled bradykinin ([3H]BKN) and 14C-labeled inulin ([14C]In) were simultaneously microinfused into proximal or distal tubules in Inactin-anesthetized rats, and urinary excretion and tubular transit times were measured. In other experiments higher doses of [3H]BKN were microinfused and intact peptide and its metabolites identified and quantified by two-dimensional peptide mapping. The site of infusion was identified by neoprene injection and microdissection. Urinary recovery of 3H label was 24.1% when proximal tubules were infused and 98.0% when distal tubules were infused. For proximal tubules, 85% of 3H activity recovered from urine consisted of metabolites (81%[3H]Pro and 4% [3H]Arg1-Phe5) and 15% was intact BKN. Urinary recoveries of [3H]BKN and metabolites were unrelated to tubular length. With distal tubules all 3H activity appeared as intact BKN. Excretion curves of simultaneously infused [3H]BKN and [14C]In showed no marked differences in configuration for either proximal or distal or distal tubules. We suggested that removal of [3H]BKN by proximal tubular cells occurs by rapid enzymatic cleavage at the luminal surface with reabsorption of most of the products and excretion of the remainder.

Animals↗
PubMed1976

Inhibition of proximal tubular hydrolysis and reabsorption of bradykinin by peptides.

[3H] bradykinin ([3H] BKN) was microinfused alone or in the presence of a 390- or 780-fold excess of BKN or angiotensin I (AI) into proximal tubules in Inactin-anesthetized rats. Urinary excretion of 3H-labeled material was measured, and intact peptide and its metabolites were identified and quantified. When [3H] BKN was administered with BKN or AI, urinary recovery of 3H-labeled material was increased in a manner directly proportional to tubular length, suggesting that reabsorption of [3H] BKN is related to extent of tubular contact. BKN and AI were equally effective in inhibiting the reabosroption of [3H] BKN and its metabolites from proximal tubular fluid. In contrast, BKN but not AI effectively inhibited the enzymatic hydrolysis of [3H] BKN in the proximal tubule, The data suggest that the proximal tubular mechanism for reabsorbing BKN and its metabolites is of high capacity but not high specificity and that the mechanisms for enzymatic cleavage and reabsorption of BKN and its metabolites may had different specificites and capacities.

Angiotensin II↗